Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Retained Earnings: 2019-2024

Historic Retained Earnings for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to -$1.8 billion.

  • Allogene Therapeutics' Retained Earnings fell 12.05% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 12.05%. This contributed to the annual value of -$1.8 billion for FY2024, which is 16.49% down from last year.
  • Latest data reveals that Allogene Therapeutics reported Retained Earnings of -$1.8 billion as of FY2024, which was down 16.49% from -$1.6 billion recorded in FY2023.
  • Over the past 5 years, Allogene Therapeutics' Retained Earnings peaked at -$646.3 million during FY2020, and registered a low of -$1.8 billion during FY2024.
  • In the last 3 years, Allogene Therapeutics' Retained Earnings had a median value of -$1.6 billion in 2023 and averaged -$1.5 billion.
  • Data for Allogene Therapeutics' Retained Earnings shows a maximum YoY plummeted of 63.17% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Allogene Therapeutics' Retained Earnings stood at -$646.3 million in 2020, then plummeted by 38.40% to -$894.6 million in 2021, then tumbled by 38.05% to -$1.2 billion in 2022, then declined by 26.50% to -$1.6 billion in 2023, then fell by 16.49% to -$1.8 billion in 2024.